WuXi AppTec Co Ltd H
- Industry
- Pharma R&D Outsourcing
- Exchange
- HK
- Country
- Hong Kong
- Employees
- 35,584
- Website
- www.wuxiapptec.com
Composite valuation range · conservative HK$120–HK$136 / fair HK$185–HK$245 / optimistic HK$300–HK$330. At HK$212.4, Within the fair intrinsic-value range.
At publication HK$199.1 (Aug 12, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
History
WuXi AppTec was founded in 2000 when Li Ge returned to China and, with co-founders Liu Xiaozhong and Zhang Zhaohui, established its R&D base in Wuxi and an operations center in Shanghai, starting as a chemistry-synthesis CRO serving overseas drug makers. It listed on the NYSE in August 2007 (US$14 per ADS), was taken private in 2015 at a market capitalization of about US$3.3 billion, and was split into multiple platforms before returning to the A-share market in May 2018 (offer price 21.6 yuan) and listing H shares in December 2018 (offer price HK$68, net proceeds of about HK$7.55 billion). The company is headquartered in Shanghai and employs 33,834 people.
Industry position
WuXi AppTec is a global contract research, development and manufacturing (CRDMO) provider for small-molecule drugs, operating through WuXi Chemistry, WuXi Testing, WuXi Biology and Others segments. Its global small-molecule CDMO market share is about 9.6% (IQVIA), and it holds roughly 35% of China's small-molecule CDMO market, ranking first; over the past five years about 21% of FDA-approved small-molecule new drugs involved the company. In 2025 it carried 3,452 molecules in its small-molecule pipeline, and its adjusted gross margin of 48.2% and net margin of 32.9% were the highest among global CXO peers.